PIP5K1C

protein-coding

phosphatidylinositol-4-phosphate 5-kinase type 1 gamma

Gene summary

This locus encodes a type I phosphatidylinositol 4-phosphate 5-kinase. The encoded protein catalyzes phosphorylation of phosphatidylinositol 4-phosphate, producing phosphatidylinositol 4,5-bisphosphate. This enzyme is found at synapses and has been found to play roles in endocytosis and cell migration. Mutations at this locus have been associated with lethal congenital contractural syndrome. Alternatively spliced transcript variants encoding different isoforms have been described.[provided by RefSeq, Sep 2010]

MANE transcript

NM_012398.3

Inheritance

AR, AD

ClinVar variants

P:10U:138B:56

Top phenotype

Lethal congenital contractural syndrome 3

gnomAD constraint

pLI —, LoF o/e 0.15

Max pathogenic AF

—

Genomic locus

chr19:3,630,183-3,700,468

External References & Databases

Transcript & Mutation Effects

hg38 • Region Span ~70.3 kb
Loading mutation effect viewer...

GenCC Phenotypes & Disease Associations

Curated gene-disease validity assertions and inheritance patterns

lethal congenital contracture syndrome 3LIMITED

Inheritance Pattern: AR

Disease ID:MONDO:0012656

Submitter: G2P

complex neurodevelopmental disorderMODERATE

Inheritance Pattern: AD

Disease ID:MONDO:0100038

Submitter: Ambry Genetics

lethal congenital contracture syndrome 3STRONG

Inheritance Pattern: AR

Disease ID:MONDO:0012656

Submitter: PanelApp Australia

complex neurodevelopmental disorderSTRONG

Inheritance Pattern: AD

Disease ID:MONDO:0100038

Submitter: PanelApp Australia

PIP5K1C-related neurodevelopmental disorderDEFINITIVE

Inheritance Pattern: AD

Disease ID:MONDO:1010145

Submitter: ClinGen

*PIP5K1C* encodes phosphatidylinositol phosphate kinase type 1 gamma (PIP5KIγ), which phosphorylates phosphatidylinositol 4-phosphate (PI4P) to produce phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2), a membrane lipid that plays essential roles in multiple cellular processes in the brain. *PIP5K1C* was first reported in relation to autosomal dominant PIP5K1C-related neurodevelopmental disorder in 2023 (Morleo et al., PMID: 37451268). Affected individuals present with developmental delay, intellectual disability, acquired microcephaly, seizures, visual abnormalities, dysmorphic features, and brain MRI abnormalities. Three *de novo* missense variants that have been reported in 9 probands in one publication (PMID: 37451268) are included in this curation. One variant, p.Tyr221Cys, was identified in 6 unrelated individuals. The three reported variants are located in the catalytic domain of the PIP5KIγ protein kinase. Additional *de novo* missense variants have been reported in individuals with developmental disorders (PMID: 33057194), but they were not included in this curation because there is no functional evidence supporting their pathogenicity. The mechanism of pathogenicity is reported to be gain of function, resulting in increased PI(4,5)P2 levels. Consistent with this mechanism, increased PI(4,5)P2 levels due to pathogenic mutations in phosphatases that dephosphorylate PI(4,5)P2 have been implicated in neurodevelopmental disorders, including Lowe (*OCRL*) and Joubert (*INPP5E*) syndromes and congenital muscular dystrophy with cataracts and intellectual disability (*INPP5K*) (PMID: 37451268). This gene-disease relationship is also supported by experimental evidence, including functional alteration in patient cells, shared biochemical function with established disease genes, and zebrafish models expressing patient variants that recapitulate aspects of the human phenotype (PMID: 37451268). Of note, biallelic variants in *PIP5K1C* leading to loss of function have been reported in relation to autosomal recessive lethal congenital contractural syndrome 3 (PMIDs: 17701898, 38491417). This assertion will be assessed separately. In summary, there is definitive evidence supporting the relationship between *PIP5K1C* and autosomal dominant PIP5K1C-related neurodevelopmental disorder. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This gene-disease pair was originally evaluated by the ClinGen Intellectual Disability and Autism Gene Curation Expert Panel on May 7, 2025. It was reevaluated on October 14, 2026 (SOP Version 12). As a result of this reevaluation, no new cases were found but the classification increased from Strong to Definitive because no contradictory evidence has emerged in the three years since the first publication.

neurodevelopmental disorderMODERATE

Inheritance Pattern: AD

Disease ID:MONDO:0700092

Submitter: G2P

lethal congenital contracture syndrome 3STRONG

Inheritance Pattern: AR

Disease ID:MONDO:0012656

Submitter: Labcorp Genetics (formerly Invitae)

lethal congenital contracture syndrome 3SUPPORTIVE

Inheritance Pattern: AR

Disease ID:MONDO:0012656

Submitter: Orphanet

Clinical Genomic Database (CGD)

Lethal congenital contractural syndrome 3AR

Manifestation: Musculoskeletal

Intervention: General

Rationale: Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing

Refs: 17701898Source: CGD (NHGRI)

ClinVar Associated Diseases & Phenotypes

Reported disease conditions connected to PIP5K1C variants in ClinVar

9 Conditions Cataloged
not providedTotal: 123
Inborn genetic diseasesTotal: 100
not specifiedTotal: 25
PIP5K1C-related disorderTotal: 15
Lethal congenital contracture syndrome 3Total: 6
NEURODEVELOPMENTAL DISORDER WITH INTELLECTUAL, VISUAL, AND LANGUAGE IMPAIRMENTTotal: 3
PIP5K1C-related neurodevelopmental disorderTotal: 2
Miyoshi muscular dystrophy 1Total: 1

ClinVar Variants & Pathogenicity by Type

Statistics based on transcript NM_012398.3. Only rare variants are included.

We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.

Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.

EffectPLPVUSLBBSum
synonymous
42
clinvar
3
clinvar
45
missense
4
clinvar
3
clinvar
131
clinvar
10
clinvar
1
clinvar
149
nonsense
1
clinvar
1
start loss
0
frameshift
1
clinvar
1
clinvar
4
clinvar
6
splice donor/acceptor (+/-2bp)
1
clinvar
2
clinvar
3
Total64138524204

Highest pathogenic variant AF is 0.000017970164

Loading ClinVar variants...

Transcript Catalog

Annotated transcript isoforms across RefSeq and Ensembl databases

Showing 4 of 64 transcripts
Transcript IDSourceProtein IDCoding ExonsMANE Status
NM_012398.3RefSeqNP_036530.118MANE Select
ENST00000335312.8EnsemblENSP00000335333.318MANE Select
NM_001195733.2RefSeqNP_001182662.117Standard
NM_001300849.2RefSeqNP_001287778.117Standard

Gene Ontology (GO) Annotations & Pathways

Biological processes, molecular functions, cellular components and pathways

Pathways ConsensusPathDB

  • Focal adhesion - Homo sapiens (human)
  • Fc gamma R-mediated phagocytosis - Homo sapiens (human)
  • Inositol phosphate metabolism - Homo sapiens (human)
  • Choline metabolism in cancer - Homo sapiens (human)
  • Endocytosis - Homo sapiens (human)

Biological Process

  • phosphatidylinositol biosynthetic process
  • phagocytosis
  • regulation of phosphatidylinositol 3-kinase signaling
  • synaptic vesicle exocytosis
  • actin cytoskeleton organization

Molecular Function

  • protein binding
  • ATP binding
  • 1-phosphatidylinositol-4-phosphate 5-kinase activity
  • 1-phosphatidylinositol-3-phosphate 4-kinase activity
  • phosphatidylinositol-3,4-bisphosphate 5-kinase activity

Cellular Component

  • phagocytic cup
  • uropod
  • nucleoplasm
  • cytosol
  • focal adhesion

gnomAD Constraint

Source: gnomAD

Gene type
protein_coding
Transcript type
protein_coding
Transcript
ENST00000335312
Coding exons
17
Length
70297
Individuals with no LoFs
125726
Homozygous LoFs
0
Heterozygous LoFs
16
Defined
125742
p
0.0000636
Z-ScoreObservedExpectedObserved/ExpectedMutation RateTotal Possible
Missense2.293004340.6900.00003284315
Missense (PolyPhen)97195.550.496031867
Synonymous-3.602672021.320.00001751327
Loss of Function4.57533.60.1490.00000164402

Population LoF Frequency

PopulationCAFp-valueStatus
African0.000130.00012rare
Latino/Admixed American0.0000290.000029rare
Ashkenazi Jewish00.0absent
East Asian0.000160.00016rare
Finnish00.0absent
European (Non-Finnish)0.0000810.000079rare
South Asian0.0000330.000033rare
Other00.0absent

dbNSFP Gene Annotations

Source: dbNSFP

Function
FUNCTION: Catalyzes the phosphorylation of phosphatidylinositol 4- phosphate (PtdIns4P) to form phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2). PtdIns(4,5)P2 is involved in a variety of cellular processes and is the substrate to form phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P3), another second messenger. The majority of PtdIns(4,5)P2 is thought to occur via type I phosphatidylinositol 4-phosphate 5-kinases given the abundance of PtdIns4P. Participates in a variety of cellular processes such as vesicle mediated transport, cell adhesion, cell polarization and cell migration. Together with PIP5K1A is required for phagocytosis, but they regulate different types of actin remodeling at sequential steps. Promotes particle attachment by generating the pool of PtdIns(4,5)P2 that induces controlled actin depolymerization to facilitate Fc-gamma-R clustering. Mediates RAC1-dependent reorganization of actin filaments. Required for synaptic vesicle transport. Controls the plasma membrane pool of PtdIns(4,5)P2 implicated in synaptic vesicle endocytosis and exocytosis. Plays a role in endocytosis mediated by clathrin and AP-2 (adaptor protein complex 2). Required for clathrin-coated pits assembly at the synapse. Participates in cell junction assembly. Modulates adherens junctions formation by facilitating CDH1 trafficking. Required for focal adhesion dynamics. Modulates the targeting of talins (TLN1 and TLN2) to the plasma membrane and their efficient assembly into focal adhesions. Regulates the interaction between talins (TLN1 and TLN2) and beta-integrins. Required for uropodium formation and retraction of the cell rear during directed migration. Has a role in growth factor- stimulated directional cell migration and adhesion. Required for talin assembly into nascent adhesions forming at the leading edge toward the direction of the growth factor. Negative regulator of T-cell activation and adhesion. Negatively regulates integrin alpha-L/beta-2 (LFA-1) polarization and adhesion induced by T-cell receptor. Together with PIP5K1A has a role during embryogenesis and together with PIP5K1B may have a role immediately after birth. {ECO:0000269|PubMed:12422219, ECO:0000269|PubMed:12847086, ECO:0000269|PubMed:17261850, ECO:0000269|PubMed:17635937}.;
Disease
DISEASE: Lethal congenital contracture syndrome 3 (LCCS3) [MIM:611369]: A form of lethal congenital contracture syndrome, an autosomal recessive disorder characterized by degeneration of anterior horn neurons, extreme skeletal muscle atrophy, and congenital non-progressive joint contractures (arthrogryposis). The contractures can involve the upper or lower limbs and/or the vertebral column, leading to various degrees of flexion or extension limitations evident at birth. LCCS3 patients present at birth with severe multiple joint contractures and severe muscle wasting and atrophy, mainly in the legs. Death occurs minutes to hours after birth due to respiratory insufficiency. The phenotype can be distinguished from that of LCCS1 by the absence of hydrops, fractures and multiple pterygia, and from LCCS2 by the absence of neurogenic bladder defect. {ECO:0000269|PubMed:17701898}. Note=The disease is caused by mutations affecting the gene represented in this entry.;

Recessive Scores

pRec
0.167

Intolerance Scores

LoFtool
0.269
RVIS EVS
-0.31
RVIS percentile EVS
32.23

Essentials

Essential (CRISPR)
N
Essential (CRISPR2)
N
Essential (gene trap)
N
Indispensability pred.
E
Indispensability score
0.981

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium
For research and educational, non-commercial use only. Not for clinical or diagnostic use. GeneBe does not provide medical advice. Data use for AI modeling is prohibited: if used, the cost is $0.001 per byte of downloaded uncompressed data.